Wall Street PR

Before You Trade: Double Eagle Petroleum Co (NASDAQ:DBLE), Clovis Oncology Inc (NASDAQ:CLVS), Conatus Pharmaceuticals Inc (NASDAQ:CNAT)

Boston, MA 03/27/2014 (wallstreetpr) – The anticipated change of guard and name at Double Eagle Petroleum Co (NASDAQ:DBLE) seem to be taken positively among investors. Moreover, promises by the company to expand its operations, attract more industry experts and boost income are all coming as good news to the shareholders. The company, in a statement, said that it will have a new CEO effective April 1, in the form of Charles F. Chambers, taking over the mantle from Richard D. Dole. The company also said it will take up a new name as Escalera Resources Co. and its senior leadership will have base in Houston. Mr. Dole, after exiting CEO role, will become vice chair of the company’s board and help with other transition matters. Banking on the 40 years experience of Mr. Chambers who will assume of CEO position in the company, Double Eagle Petroleum Co (NASDAQ:DBLE) hopes that it will be able to fix its present challenges, introduce new products and grow. Shares of the company jumped 13.36 percent to $2.80 during Wednesday session. Earlier on the day shares escalated to highs of $2.94, having opened at $2.50 and changing above average volume to close.

Clovis Oncology Inc (NASDAQ:CLVS) stock was initiated by investment analysts at Goldman Sachs (NYSE:GS). In a research note to investors, the analysts planted neutral rating on the stock and issued $90 price target. Looking at the previous closing price of CLVS, Goldman’s price target implies potential upside of more than 21 percent. On average, the stock carries price target of 90.33, and consensus rating of buy. The company reported its most recent quarter on February 27, announcing net loss of $0.92 per share, against the expected net loss of $0.78. Analysts are modeling net loss of 3.92 per share in the current year. Shares of the company jumped 4.91 percent to close at $77.50.

On no significant company-news, Conatus Pharmaceuticals Inc (NASDAQ:CNAT) jumped 6.23 percent to $10.06 Wednesday, just when it had dropped. The jump in the stock signaled improving sentiment in the stock among investors. The previous session saw a significant amount of shares changing hands between $9.60 and $10.49., having opened at $9.69. The stock of the $157.14 million market capped company shifted hands between $5.76 and $15.67 low and high respectively in the past year.

Published by Benjamin Roussey

Benjamin Roussey is from Sacramento, California. He has two master’s degrees and served four years in the U.S. Navy. His bachelor’s degree is from CSUS (1999) where he was on a baseball pitching scholarship. His second master’s degree is an MBA in Global Management from the University of Phoenix (2006). He has worked for small businesses, public agencies, and large corporations. He has lived in Korea and Saudi Arabia where he was an ESL instructor. Benjamin spends his time in between Northern California and Cabo San Lucas, Mexico, committing himself to his craft of freelance and website writing. http://www.facebook.com/ben.rouss